Genmab A/S (FRA:GE9)

Market Cap	15.29B +29.3%
Revenue (ttm)	3.17B +19.2%
Net Income	820.19M -15.0%
EPS	13.09 -12.3%
Shares Out	n/a
PE Ratio	18.64
Forward PE	21.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	240.00
Previous Close	242.40
Day's Range	240.00 - 240.00
52-Week Range	155.95 - 303.80
Beta	n/a
RSI	38.54
Earnings Date	Feb 17, 2026

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 2,681
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GE9

Financial Performance

In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.

Financial numbers in USD